Fig. 1

A schematic diagram showing that a PF127 hydrogel loaded with cisplatin and ropivacaine (PFCR) relieves chemotherapy-induced peripheral neuropathic pain (CIPNP) and potentiates chemotherapy efficacy by enhancing T cell immunity. A Preparation of PFCR hydrogel. B Mechanism of PFCR in relieving CIPNP and anti-tumor. Ropivacaine released from PFCR blocks the transmission of pain signal and reduces the number of pERK positive nerons in DRG, alleviating CIPNP. Cisplatin released from PFCR directly kills tumors, while ropivacaine enhances the expression of MHC-I in tumor cells, facilitates their recognition by CD8⁺ T cells, which further kills tumor cells